Select year

2025 2024 2023 2022 2021 Earlier

shown/page

5

2020.12.16

Chipscreen and HISUN reach a strategic cooperation
Chipscreen and HISUN reach a strategic cooperation

2020.06.24

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

2020.03.24

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

2019.12.03

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

2019.10.09

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development
Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com